Tabeta H, Sawada M, Honda A, Takizawa H, Kikuchi N
Internal Medicine Clinic, Shioya Hospital.
Jpn J Antibiot. 1987 Dec;40(12):1969-74.
Norfloxacin (NFLX), an oral antibacterial agent of new quinolone derivative, was administered at daily doses of 300-600 mg t.i.d. to 20 aged patients with respiratory tract infections. The results obtained are summarized as follows. 1. Clinical efficacies were moderate in 6 patients with upper respiratory tract infections, and moderate in 11 patients and fair in 3 patients with lower respiratory tract infections. In the 20 patients, overall clinical efficacies were moderate in 17 patients, hence the efficacy rate was 85%. 2. Bacteriologically, causative organisms were detected in 10 of the 14 cases with lower respiratory tract infections. In these cases, bacteriological responses were "eradicated" in 9 cases, "decreased" in 1 case and "unknown" in 1 case, the rate of eradication was 90%. 3. No adverse reactions or abnormal laboratory test values were observed.
诺氟沙星（NFLX）是一种新型喹诺酮衍生物口服抗菌剂，对20例老年呼吸道感染患者每日3次，每次300 - 600毫克给药。所得结果总结如下。1. 6例上呼吸道感染患者临床疗效为中等，11例下呼吸道感染患者临床疗效为中等，3例为尚可。20例患者中，17例总体临床疗效为中等，有效率为85%。2. 细菌学方面，14例下呼吸道感染病例中有10例检测到病原体。在这些病例中，细菌学反应“根除”9例，“减少”1例，“不明”1例，根除率为90%。3. 未观察到不良反应或实验室检查值异常。
